<DOC>
	<DOCNO>NCT00115830</DOCNO>
	<brief_summary>The purpose study investigate effect atorvastatin ( Lipitor ) rosuvastatin ( Crestor ) , United States Food Drug Administration ( FDA ) approve drug commonly prescribe doctor low cholesterol , certain function platelet ( cell cause blood clot ) , white blood cell ( cell responsible inflammation ) , blood flow regulation artery . This important look way effectively prevent atherosclerosis ( plaque buildup blood vessel ) heart disease . Many study demonstrate drug effective reduce inflammation stabilize plaque . We interested well understanding effect medicine inflammation ( pain swell ) mechanism act . Hypothesis : Atorvastatin ( 40mg ) reduce inflammatory marker activity Rosuvastatin ( 10mg ) spite equal LDL-C reduction .</brief_summary>
	<brief_title>Rho Kinase Patients With Atherosclerosis</brief_title>
	<detailed_description>A double-blind control trial two arm conduct Brigham Women â€™ Hospital ( BWH ) . We screen subject stable atherosclerosis complete enrollment 40 subject study ( see inclusion exclusion criterion section ) . A central pharmacist BWH randomize patient 40mg atorvastatin ( n=20 ) 10mg rosuvastatin ( n=20 ) 28 day . If patient already statin two-week washout period require prior trial initiation . Our subject , clinician , data collector , outcome assessor statistician blind regard patient allocation . There total 3 visit patient : short screen visit , initial visit baseline data ( 90 min . ) final visit 28 day . Our participant ask take medication every day time 9pm 10pm . Each visit take place 7am 9am . Patients instruct fast overnight minimum 8hrs . They also advise make change current medication lifestyle 28 day study record diary side effect , miss dos , change concomitant medication .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male female subject age 40 80 year Documented stable atherosclerosis angiography vascular ultrasound ( 20 % luminal narrowing ) , previous myocardial infarction , ischemic stroke , peripheral arterial disease type 2 diabetes mellitus ( coronary heart disease ( CHD ) risk equivalent Adult Treatment Program ( ATP ) III guideline ) LDLcholesterol &gt; 100mg/dL ( indication treat statin ) Written informed consent Primary care physician authorization letter participate study . Inability give consent Premenopausal woman Current use antibiotic , antiinflammatory immunosuppressant drug History LFT &gt; 2 time upper normal limit History myopathy/myositis CPK &gt; 10 time upper normal limit CPK normal limit study onset Any evidence inflammatory , infectious neoplastic disease History CABG , PCI acute ischemic syndrome precede 3 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>